Pfizer/BioNTech makes surprise choice in final dash to October finish line for Covid-19 vaccine
Pfizer and BioNTech have zeroed in on an mRNA vaccine candidate to take into a pivotal study — and it’s not the one that got analysts and investors excited from a recent release of data.
On the same day Moderna began the US’ first Phase III Covid-19 vaccine study, the partners announced late in the evening that they have started their own rival effort with BNT162b2. A two-dose regimen at a 30 µg dose will be tested.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.